PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 21, 1995New England Journal of Medicine1,787 citationsOpen Access

A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction

View Full Paper
LKLars KøberCTChristian Torp‐PedersenJCJan E. Carlsen

Structured PICO

Does trandolapril reduce mortality and severe heart failure in patients with reduced left ventricular function after myocardial infarction?

P
Population
Patients with reduced left ventricular function soon after myocardial infarction
I
Intervention
Trandolapril (long-term treatment)
O
Outcome
Overall mortality, mortality from cardiovascular causes, sudden death, and the development of severe heart failurehard clinical

Long-term treatment with trandolapril significantly reduces mortality and the development of severe heart failure in patients with left ventricular dysfunction after myocardial infarction.

Abstract

Long-term treatment with trandolapril in patients with reduced left ventricular function soon after myocardial infarction significantly reduced the risk of overall mortality, mortality from cardiovascular causes, sudden death, and the development of severe heart failure. That mortality was reduced in a randomized study enrolling 25 percent of consecutive patients screened should encourage the selective use of ACE inhibition after myocardial infarction.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Køber et al. (1995) studied this question.

synapsesocial.com/papers/69d56ec075589c71d767d5cahttps://doi.org/10.1056/nejm199512213332503
Ask AI
Helpful
Bookmark
Share
View Full Paper